{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:44:39Z","timestamp":1792003479308,"version":"4.4.0"},"reference-count":153,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T00:00:00Z","timestamp":1646352000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJERPH"],"abstract":"<jats:p>Flu is a serious health, medical, and economic problem, but no therapy is yet available that has satisfactory results and reduces the occurrence of these problems. Nearly 20 years after the registration of the previous therapy, baloxavir marboxil, a drug with a new mechanism of action, recently appeared on the market. This is a promising step in the fight against the influenza virus. This article presents the possibilities of using all available antiviral drugs specific for influenza A and B. We compare all currently recommended anti-influenza medications, considering their mechanisms of action, administration, indications, target groups, effectiveness, and safety profiles. We demonstrate that baloxavir marboxil presents a similar safety and efficacy profile to those of drugs already used in the treatment of influenza. Further research on combination therapy is highly recommended and may have promising results.<\/jats:p>","DOI":"10.3390\/ijerph19053018","type":"journal-article","created":{"date-parts":[[2022,3,6]],"date-time":"2022-03-06T20:38:16Z","timestamp":1646599096000},"page":"3018","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":141,"title":["Antiviral Drugs in Influenza"],"prefix":"10.3390","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2412-8220","authenticated-orcid":false,"given":"Magdalena","family":"\u015awierczy\u0144ska","sequence":"first","affiliation":[{"name":"Centre for Preclinical Research and Technology CePT, Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Banacha 1B, 02-097 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6294-3256","authenticated-orcid":false,"given":"Dagmara M.","family":"Mirowska-Guzel","sequence":"additional","affiliation":[{"name":"Centre for Preclinical Research and Technology CePT, Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Banacha 1B, 02-097 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8776-0069","authenticated-orcid":false,"given":"Edyta","family":"Pindelska","sequence":"additional","affiliation":[{"name":"Department of Analytical Chemistry and Biomaterials, Faculty of Pharmacy, Medical University of Warsaw, Banacha 1B, 02-093 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,3,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.cnur.2019.02.009","article-title":"Seasonal Influenza (Flu)","volume":"54","author":"Keilman","year":"2019","journal-title":"Nurs. Clin. N. Am."},{"key":"ref_2","unstructured":"WHO (2021, October 13). Influenza. Available online: https:\/\/www.who.int\/teams\/health-product-policy-and-standards\/standards-and-specifications\/vaccines-quality\/influenza."},{"key":"ref_3","unstructured":"WHO (2021, October 13). Estimate of Influenza Deaths Due to Respiratory Disease. Available online: https:\/\/www.who.int\/teams\/global-influenza-programme\/surveillance-and-monitoring\/burden-of-disease."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3960","DOI":"10.1016\/j.vaccine.2018.05.057","article-title":"Economic burden of seasonal influenza in the United States","volume":"36","author":"Putri","year":"2018","journal-title":"Vaccine"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s10198-020-01172-1","article-title":"Incidence and costs of hospitalized adult influenza patients in The Netherlands: A retrospective observational study","volume":"21","author":"Marbus","year":"2020","journal-title":"Eur. J. Health Econ."},{"key":"ref_6","unstructured":"WHO (2021, October 13). Seasonal Influenza. Available online: https:\/\/www.who.int\/health-topics\/influenza-seasonal#tab=tab_1."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s40265-020-01350-8","article-title":"Baloxavir Marboxil: A Review in Acute Uncomplicated Influenza","volume":"80","author":"Shirley","year":"2020","journal-title":"Drugs"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1007\/s12098-020-03214-1","article-title":"Influenza","volume":"87","author":"Dharmapalan","year":"2020","journal-title":"Indian J. Pediatrics"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1345\/aph.10118","article-title":"Neuraminidase Inhibitors: Zanamivir and Oseltamivir","volume":"35","author":"McNicholl","year":"2001","journal-title":"Ann. Pharmacother."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.vaccine.2008.07.039","article-title":"The biology of Influenza viruses","volume":"265","author":"Bouvier","year":"2008","journal-title":"Vaccine"},{"key":"ref_11","unstructured":"(2021, October 13). FDA\u201441st Edition\u20142021\u2014Approved Drug Product List. Prescription Drug Product List. Available online: https:\/\/thefdalawblog.com\/wp-content\/uploads\/2021\/01\/Orange-Book-41st-Annual.pdf."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/S0140-6736(99)11433-8","article-title":"Influenza virus neuraminidase inhibitors","volume":"355","author":"Gubareva","year":"2000","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1126\/science.1232552","article-title":"Mechanism-Based Covalent Neuraminidase Inhibitors with Broad-Spectrum Influenza Antiviral Activity","volume":"340","author":"Kim","year":"2013","journal-title":"Science"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1056\/NEJMra050740","article-title":"Neuraminidase Inhibitors for Influenza","volume":"353","author":"Moscona","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_15","first-page":"153","article-title":"Influenza A: Understanding the Viral Life Cycle","volume":"82","author":"Samji","year":"2009","journal-title":"Yale J. Biol. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S0149-2918(01)80042-4","article-title":"Zanamivir and oseltamivir: Two new options for the treatment and prevention of influenza","volume":"23","author":"Dreitlein","year":"2001","journal-title":"Clin. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.coviro.2019.01.006","article-title":"Baloxavir marboxil: The new influenza drug on the market","volume":"35","author":"Shaw","year":"2019","journal-title":"Curr. Opin. Virol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Laborda, P., Wang, S.-Y., and Voglmeir, J. (2016). Influenza Neuraminidase Inhibitors: Synthetic Approaches, Derivatives and Biological Activity. Molecules, 21.","DOI":"10.3390\/molecules21111513"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Dou, D., Revol, R., \u00d6stbye, H., Wang, H., and Daniels, R. (2018). Influenza A Virus Cell Entry, Replication, Virion Assembly and Movement. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.01581"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1055\/s-2007-979191","article-title":"Possible use of Amantadine in depression","volume":"32","author":"Hubert","year":"1999","journal-title":"Pharmacopsychiatry"},{"key":"ref_21","first-page":"2288","article-title":"Anti-influenza A viral drug-amantadine","volume":"58","author":"Tokimatsu","year":"2000","journal-title":"Nihon Rinsho"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"7977","DOI":"10.1021\/jp800171m","article-title":"A Secondary Gate as a Mechanism for Inhibition of the M2 Proton Channel by Amantadine","volume":"112","author":"Yi","year":"2008","journal-title":"J. Phys. Chem. B"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"11872","DOI":"10.1021\/bi9014488","article-title":"Design and Pharmacological Characterization of Inhibitors of Amantadine-Resistant Mutants of the M2 Ion Channel of Influenza A Virus","volume":"48","author":"Balannik","year":"2009","journal-title":"Biochemistry"},{"key":"ref_24","first-page":"399","article-title":"Twenty-five years of amantadine therapy in Parkinson\u2019s disease","volume":"46","author":"Danielczyk","year":"1995","journal-title":"J. Neural Transm. Suppl."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"454","DOI":"10.7326\/0003-4819-94-4-454","article-title":"Pharmacokinetics of Amantadine Hydrochloride in Subjects with Normal and Impaired Renal Function","volume":"94","author":"Horadam","year":"1981","journal-title":"Ann. Intern. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/01376517-199010000-00011","article-title":"Amantadine Hydrochloride: Current and News Uses","volume":"22","author":"Roin","year":"1990","journal-title":"J. Neurosci. Nurs."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Dong, G., Peng, C., Luo, J., Wang, C., Han, L., Wu, B., Ji, G., and He, H. (2015). Adamantane-resistant influenza a viruses in the world (1902\u20132013): Frequency and distribution of M2 gene mutations. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0119115"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Jefferson, T., Demicheli, V., Di Pietrantonj, C., and Rivetti, D. (2006). Amantadine and rimantadine for influenza A in adults. Cochrane Database Syst. Rev., CD001169.","DOI":"10.1002\/14651858.CD001169.pub3"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0149-7634(96)00037-1","article-title":"Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents\u2014Preclinical studies","volume":"21","author":"Danysz","year":"1997","journal-title":"Neurosci. Biobehav. Rev."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1080\/14656566.2019.1612365","article-title":"Evaluating ADS5102 (amantadine) for the treatment of Parkinson\u2019s disease patients with dyskinesia","volume":"20","author":"Kuhn","year":"2019","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s40262-018-0663-4","article-title":"Pharmacokinetics of ADS-5102 (Amantadine) Extended Release Capsules Administered Once Daily at Bedtime for the Treatment of Dyskinesia","volume":"58","author":"Hauser","year":"2019","journal-title":"Clin Pharmacokinet."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clineuro.2020.105815","article-title":"The role of amantadine in cognitive recovery early after traumatic brain injury: A systematic review","volume":"194","author":"Loggini","year":"2020","journal-title":"Clin. Neurol. Neurosurg."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.mayocp.2018.10.021","article-title":"Amantadine Use for Postconcussion Syndrome","volume":"94","author":"Carabenciov","year":"2019","journal-title":"Mayo Clin. Proc."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S1474-4422(20)30354-9","article-title":"Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: A randomised, placebo-controlled, crossover, double-blind trial","volume":"20","author":"Nourbakhsh","year":"2020","journal-title":"Lancet Neurol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"102163","DOI":"10.1016\/j.msard.2020.102163","article-title":"Adamantanes might be protective from COVID-19 in patients with neurological diseases: Multiple sclerosis, parkinsonism and cognitive impairment","volume":"42","author":"Rejdak","year":"2020","journal-title":"Mult. Scler. Relat. Disorders Elsevier"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1007\/s43440-020-00168-1","article-title":"Observational study of people infected with SARS-CoV-2, treated with amantadine","volume":"72","year":"2020","journal-title":"Pharmacol. Rep."},{"key":"ref_37","first-page":"1","article-title":"Neuraminidase inhibitors as a strategy for influenza treatment: Pros, cons and future perspectives","volume":"1465\u20136566","author":"Bassetti","year":"2019","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.antiviral.2018.07.001","article-title":"Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors and status of novel antivirals, 2016\u20132017","volume":"157","author":"Lackenby","year":"2018","journal-title":"Antivir. Res."},{"key":"ref_39","first-page":"751","article-title":"Influenza: Diagnosis and Treatment","volume":"100","author":"Gaitonde","year":"2019","journal-title":"Am. Fam. Physician"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/phar.2370","article-title":"Oseltamivir for All: Should It Become an Over-the-Counter Medication for Influenza Treatment?","volume":"40","author":"Rech","year":"2020","journal-title":"Pharmacother. J. Hum. Pharmacol. Drug Ther."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1056\/NEJM199709253371302","article-title":"Efficacy and Safety of the Neuraminidase Inhibitor Zanamivir in the Treatment of Influenzavirus Infections","volume":"337","author":"Hayden","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1021\/ja963036t","article-title":"Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: Design, synthesis and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity","volume":"119","author":"Kim","year":"1997","journal-title":"J. Am. Chem. Soc."},{"key":"ref_43","unstructured":"EMA (2021, October 13). Dectova, Summary of Product Characteristics. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/dectova-epar-product-information_en.pdf."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1093\/cid\/ciy860","article-title":"Early oseltamivir after hospital admission is associated with shortened hospitalization: A five-year analysis of oseltamivir timing and clinical outcomes","volume":"69","author":"Katzen","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1136\/thx.2009.130799","article-title":"Outcomes of adults hospitalised with severe influenza","volume":"65","author":"Lee","year":"2010","journal-title":"BMJ J. Thorax."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1093\/cid\/cis636","article-title":"Treatment with neuraminidase inhibitors for critically ill patients with influenza A (H1N1)pdm09","volume":"55","author":"Louie","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1093\/jac\/dkx271","article-title":"Safety and effectiveness of neuraminidase inhibitors for influenza treatment, prophylaxis, and outbreak control: A systematic review of systematic reviews and\/or meta-analyses","volume":"72","author":"Doll","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S2213-2600(14)70041-4","article-title":"Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: A meta-analysis of individual participant data","volume":"2","author":"Muthuri","year":"2014","journal-title":"Lancet Respir. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/s13054-019-2491-9","article-title":"Influenza virus-related critical illness: Prevention, diagnosis, treatment","volume":"23","author":"Chow","year":"2019","journal-title":"Crit. Care"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1093\/jac\/dkr089","article-title":"Benefit of early treatment with oseltamivir in hospitalized patients with documented 2009 influenza A (H1N1): Retrospective cohort study","volume":"66","author":"Hiba","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"512","DOI":"10.7326\/0003-4819-156-7-201204030-00411","article-title":"Antivirals for treatment of influenza: A systematic review and meta-analysis of observational studies","volume":"156","author":"Hsu","year":"2012","journal-title":"Ann. Intern. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/infdis\/jis726","article-title":"Impact of neuraminidase inhibitor treatment on outcomes of public health importance during the 2009\u20132010 influenza a(H1N1) pandemic: A systematic review and meta-analysis in hospitalized patients","volume":"207","author":"Muthuri","year":"2013","journal-title":"J. Infect. Dis."},{"key":"ref_53","first-page":"5","article-title":"Neuraminidase inhibitors for influenza: A systematic review and meta-analysis of regulatory and mortality data","volume":"42","author":"Heneghan","year":"2016","journal-title":"Health Technol. Assess."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/j.drudis.2020.06.004","article-title":"Oseltamivir analogs with potent anti-influenza virus activity","volume":"25","author":"Kumar","year":"2020","journal-title":"Drug Discov. Today."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"26","DOI":"10.32607\/20758251-2009-1-2-26-32","article-title":"Influenza virus neuraminidase: Structure and function","volume":"1","author":"Shtyrya","year":"2009","journal-title":"Acta Naturae."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1128\/AAC.45.12.3403-3408.2001","article-title":"Comparison of the Activities of Zanamivir, Oseltamivir, and RWJ-270201 against Clinical Isolates of Influenza Virus and Neuraminidase Inhibitor-Resistant Variants","volume":"45","author":"Gubareva","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Yin, X., Jiang, N., Shi, W., Chi, X., Liu, S., Chen, J.-L., and Wang, S. (2021). Development and Effects of Influenza Antiviral Drugs. Molecules, 26.","DOI":"10.3390\/molecules26040810"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1586\/17476348.2016.1126182","article-title":"Oseltamivir for influenza infection in children: Risks and benefits","volume":"10","author":"Esposito","year":"2015","journal-title":"Expert Rev. Respir. Med."},{"key":"ref_59","unstructured":"Sur, M., Lopez, M.J., and Baker, M.B. (2021, October 13). Oseltamivir. Available online: https:\/\/www-1ncbi-1nlm-1nih-1gov-100001atj0c66.han3.wum.edu.pl\/books\/NBK539909\/."},{"key":"ref_60","unstructured":"EMA (2021, October 13). List of Nationally Authorised Medicinal Products. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/psusa\/zanamivir-list-nationally-authorised-medicinal-products-psusa\/00003141\/201701_en.pdf."},{"key":"ref_61","unstructured":"FDA (2021, October 13). Highlights of Prescribing Information. Relenza, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/021036s025lbl.pdf."},{"key":"ref_62","unstructured":"Australia\u2019s National Science Agency (2021, October 13). Relenza\u2014The First Effective Flu-Fighter. Available online: https:\/\/www.csiro.au\/en\/research\/health-medical\/vaccines\/relenza."},{"key":"ref_63","unstructured":"EMA (2021, October 13). Dectova, Authorisation Details. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/dectova."},{"key":"ref_64","unstructured":"EMC (2021, October 13). Relenza. Available online: https:\/\/www.medicines.org.uk\/emc\/product\/3809\/smpc."},{"key":"ref_65","unstructured":"EMC (2021, October 13). Dectova. Available online: https:\/\/www.medicines.org.uk\/emc\/product\/10193\/smpc."},{"key":"ref_66","unstructured":"EMA (2021, October 13). Dectova, Assessment Report. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/dectova-epar-public-assessment-report_en.pdf."},{"key":"ref_67","unstructured":"EMA, and Tamiflu (2021, October 13). Summary of Product Characteristic. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tamiflu-epar-product-information_en.pdf."},{"key":"ref_68","unstructured":"FDA, and Tamiflu (2021, October 13). Highlights of Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/021087s068,021246s051lbl.pdf."},{"key":"ref_69","unstructured":"EMC (2021, October 13). Tamiflu. Available online: https:\/\/www.medicines.org.uk\/emc\/medicine\/20294#gref."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"851","DOI":"10.2165\/00003495-199958050-00007","article-title":"Oseltamivir","volume":"58","author":"Noble","year":"1999","journal-title":"Drugs"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1517\/14656566.2015.1066336","article-title":"Peramivir: An intravenous neuraminidase inhibitor","volume":"16","author":"McLaughlin","year":"2015","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1007\/s40265-018-0981-8","article-title":"Peramivir: A Review in Uncomplicated Influenza","volume":"78","author":"Scott","year":"2018","journal-title":"Drugs"},{"key":"ref_73","unstructured":"FDA (2021, October 13). Rapivab, Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/206426lbl.pdf."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1586\/eri.11.174","article-title":"Peramivir for the treatment of influenza","volume":"10","author":"Shetty","year":"2012","journal-title":"Expert Rev. Anti-Infect. Ther."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.ijantimicag.2012.06.017","article-title":"Safety of the long-acting neuraminidase inhibitor laninamivir octanoate hydrate in post-marketing surveillance","volume":"40","author":"Kashiwagi","year":"2012","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_76","unstructured":"ClinicalTrials.gov (2022, February 07). Efficacy and Safety Study of Laninamivir Octanoate TwinCaps\u00ae Dry Powder Inhaler in Adults with Influenza (Igloo), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT01793883?view=results."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003088-199936001-00001","article-title":"Pharmacokinetics of Zanamivir After Intravenous, Oral, Inhaled or Intranasal Administration to Healthy Volunteers","volume":"36","author":"Cass","year":"1999","journal-title":"Clin Pharmacokinet."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1128\/AAC.02330-12","article-title":"Pharmacokinetics of Zanamivir following Intravenous Administration to Subjects with and without Renal Impairment","volume":"57","author":"Weller","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0964-3397(99)80031-7","article-title":"Zanamivir (Relenza\u00ae)\u2014A new treatment for influenza","volume":"15","author":"MacConnachie","year":"1999","journal-title":"Intensive Crit. Care Nurs."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1093\/infdis\/jit467","article-title":"Safety and Pharmacokinetics of Intravenous Zanamivir Treatment in Hospitalized Adults with Influenza: An Open-label, Multicenter, Single-Arm, Phase II Study","volume":"209","author":"Marty","year":"2014","journal-title":"J. Infect. Dis."},{"key":"ref_81","unstructured":"EMA (2021, October 13). Dectova (zanamivir) An overview of Dectova and Why It Is Authorised in the EU. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/dectova-epar-medicine-overview_en.pdf."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1177\/1060028020963616","article-title":"Intravenous Zanamivir: A Viable Option for Critically Ill Patients with Influenza","volume":"55","author":"Slain","year":"2020","journal-title":"Ann. Pharmacother."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Torti, C., Mazzitelli, M., Longhini, F., Garofalo, E., Bruni, A., Giancotti, A., Barreca, G.S., Quirino, A., Liberto, M.C., and Serapide, F. (2019). Clinical outcomes of patients treated with intravenous zanamivir for severe influenza A(H1N1)pdm09 infection: A case report series. BMC Infect. Dis., 19.","DOI":"10.1186\/s12879-019-4530-1"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S2213-2600(16)30435-0","article-title":"Intravenous zanamivir or oral oseltamivir for hospitalised patients with influenza: An international, randomised, double-blind, double-dummy, phase 3 trial","volume":"5","author":"Marty","year":"2017","journal-title":"Lancet Respir. Med."},{"key":"ref_85","first-page":"481","article-title":"Intravenous zanamivir in critically ill patients due to pandemic 2009 (H I N I) influenza A virus","volume":"52","author":"Wijaya","year":"2011","journal-title":"Singap. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1542\/peds.2016-2727","article-title":"Intravenous Zanamivir in Hospitalized Patients with Influenza","volume":"140","author":"Bradley","year":"2017","journal-title":"Pediatrics"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamainternmed.2015.5747","article-title":"Treating Influenza with Neuraminidase Inhibitors","volume":"175","author":"Louie","year":"2015","journal-title":"JAMA Intern. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.antiviral.2013.08.023","article-title":"Neuraminidase inhibitors for influenza B virus infection: Efficacy and resistance","volume":"100","author":"Burnham","year":"2013","journal-title":"Antivir. Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"ii5","DOI":"10.1093\/jac\/dkq015","article-title":"Pharmacokinetics of oseltamivir: An oral antiviral for the treatment and prophylaxis of influenza in diverse populations","volume":"65","author":"Davies","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1503\/cmaj.092127","article-title":"Enteric absorption and pharmacokinetics of oseltamivir in critically ill patients with pandemic (H1N1) influenza","volume":"182","author":"Ariano","year":"2010","journal-title":"Can. Med. Assoc. J."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1002\/phar.1151","article-title":"Pharmacokinetics of Oseltamivir and Oseltamivir Carboxylate in Critically Ill Patients Receiving Continuous Venovenous Hemodialysis and\/or Extracorporeal Membrane Oxygenation","volume":"32","author":"Eyler","year":"2012","journal-title":"Pharmacother. J. Hum. Pharmacol. Drug Ther."},{"key":"ref_92","unstructured":"(2021, October 13). WHO Guidelines for Pharmacological Management of Pandemic Influenza A(H1N1) 2009 and other Influenza Viruses. Available online: https:\/\/www.who.int\/csr\/resources\/publications\/swineflu\/h1n1_guidelines_pharmaceutical_mngt.pdf."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"471","DOI":"10.2165\/00003088-199937060-00003","article-title":"Clinical Pharmacokinetics of the Prodrug Oseltamivir and its Active Metabolite Ro 64-0802","volume":"37","author":"He","year":"1999","journal-title":"Clin. Pharmacokinet."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/phar.2330","article-title":"Peramivir for Influenza A and B Viral Infections: A Pharmacokinetic Case Series","volume":"39","author":"Cies","year":"2019","journal-title":"Pharmacother. J. Hum. Pharmacol. Drug Ther."},{"key":"ref_95","unstructured":"EMA (2021, October 13). Ebilfumin. Authorisation Details., Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/ebilfumin#authorisation-details-section."},{"key":"ref_96","first-page":"17","article-title":"Is oseltamivir (Tamiflu\u00ae) safe? Re-examining the Tamiflu \u201cado\u201d from Japan","volume":"10","author":"Okamoto","year":"2010","journal-title":"Expert Rev. Pharm. Outcomes Res."},{"key":"ref_97","unstructured":"(2021, October 13). FDA-Approved Drugs, Available online: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=BasicSearch.process."},{"key":"ref_98","unstructured":"Drugs.com (2021, October 13). Tamiflu Alternatives Compared. Available online: https:\/\/www.drugs.com\/compare\/tamiflu."},{"key":"ref_99","unstructured":"EMA (2021, October 13). Alpivab, Withdrawal Marketing Authorisation in the European Union. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/public-statement\/public-statement-alpivab-withdrawal-marketing-authorisation-european-union_en.pdf."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3851\/IMP3104","article-title":"Pharmacokinetics and safety of intravenous peramivir, neuraminidase inhibitor of influenza virus, in healthy Japanese subjects","volume":"22","author":"Saisho","year":"2016","journal-title":"Antivir. Ther."},{"key":"ref_101","unstructured":"Elsevier, and Peramivir (2022, February 07). Published 4 February 2021. Available online: https:\/\/elsevier.health\/en-US\/preview\/peramivir."},{"key":"ref_102","unstructured":"DaiichiSankyo (2021, October 13). Approval for the Use of Inavir\u00ae to Prevent Influenza. Available online: https:\/\/www.daiichisankyo.com\/files\/news\/pressrelease\/pdf\/006052\/20131220_484_E.pdf."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1586\/eri.11.112","article-title":"Laninamivir octanoate: A new long-acting neuraminidase inhibitor for the treatment of influenza","volume":"9","author":"Ikematsu","year":"2011","journal-title":"Expert Rev. Anti-Infect. Ther."},{"key":"ref_104","unstructured":"(2021, October 13). Inavir\u2014Drug Information Sheet. Available online: http:\/\/k-tosaka.sakura.ne.jp\/FLU\/inavir-shiori-Eng.pdf."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1177\/0091270009356297","article-title":"Clinical Pharmacokinetics of Laninamivir, a Novel Long-Acting Neuraminidase Inhibitor, After Single and Multiple Inhaled Doses of Its Prodrug, CS-8958, in Healthy Male Volunteers","volume":"50","author":"Ishizuka","year":"2010","journal-title":"J. Clin. Pharmacol."},{"key":"ref_106","first-page":"1","article-title":"Intrapulmonary Pharmacokinetics of Laninamivir, a Neuraminidase Inhibitor, after a Single Nebulized Administration of Laninamivir Octanoate in Healthy Japanese Subjects","volume":"62","author":"Toyama","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40780-017-0094-7","article-title":"Impact of the number of repeated inhalations and patient characteristics on the residual amount of inhaled laninamivir octanoate hydrate dry powder in pediatric patients with influenza","volume":"3","author":"Murasaka","year":"2017","journal-title":"J. Pharm. Health Care Sci."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Chen, J.Y., Wei, S.-K., Lai, C.C., Weng, T.-S., and Wang, H.-H. (2020). A Meta-Analysis Comparing the Efficacy and Safety of Peramivir with Other Neuraminidase Inhibitors for Influenza Treatment. Medicina, 56.","DOI":"10.3390\/medicina56020063"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.jiac.2018.01.013","article-title":"Clinical effectiveness of four neuraminidase inhibitors (oseltamivir, zanamivir, laninamivir, and peramivir) for children with influenza A and B in the 2014\u20132015 to 2016\u20132017 influenza seasons in Japan","volume":"24","author":"Ishiguro","year":"2018","journal-title":"J. Infect. Chemother."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.2147\/DDDT.S46654","article-title":"Safety and efficacy of peramivir for influenza treatment","volume":"8","author":"Hata","year":"2014","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group (1998). Randomised trial of efficacy and safety of zanamivir for oral inhalation in treatment of influenza A and B virus infections. Lancet, 12, 1877\u20131881.","DOI":"10.1016\/S0140-6736(98)10190-3"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1086\/514136","article-title":"Effects of the Neuraminidase Inhibitor Zanamivir on Otologic Manifestations of Experimental Human Influenza","volume":"176","author":"Walker","year":"1997","journal-title":"J. Infect. Dis."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1001\/jama.282.1.31","article-title":"Zanamivir in the Prevention of Influenza Among Healthy Adults","volume":"282","author":"Monto","year":"1999","journal-title":"JAMA"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1056\/NEJM200011023431801","article-title":"Zanamivir for oral inhalation for the Prevention of Influenza in Families","volume":"343","author":"Hayden","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1086\/345722","article-title":"Zanamivir Prophylaxis: An Effective Strategy for the Prevention of Influenza Types A and B within Households","volume":"186","author":"Monto","year":"2002","journal-title":"J. Infect. Dis."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1001\/jama.283.8.1016","article-title":"Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: A randomized controlled trial. US oral neuraminidase study group","volume":"283","author":"Treanor","year":"2000","journal-title":"JAMA"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/00006454-200102000-00002","article-title":"Oral oseltamivir treatment of influenza in children","volume":"20","author":"Whitley","year":"2001","journal-title":"Pediatric Infect. Dis. J."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1056\/NEJM199910283411802","article-title":"Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza","volume":"341","author":"Hayden","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1086\/381128","article-title":"Management of influenza in households: A prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis","volume":"189","author":"Hayden","year":"2004","journal-title":"J. Infect. Dis."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1001\/jama.285.6.748","article-title":"Effectiveness of oseltamivir in preventing influenza in household contacts: A randomized controlled trial","volume":"285","author":"Welliver","year":"2001","journal-title":"JAMA"},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Duval, X., van der Werf, S., Blanchon, T., Mosnier, A., Bouscambert-Duchamp, M., Tibi, A., Enouf, V., Charlois-Ou, C., Vincent, C., and Andreoletti, L. (2010). Efficacy of Oseltamivir-Zanamivir Combination Compared to Each Monotherapy for Seasonal Influenza: A Randomized Placebo-Controlled Trial. PLoS Med., 7.","DOI":"10.1371\/annotation\/ca448e7c-fbbc-43e9-9981-108c9bfa8bce"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.antiviral.2012.08.002","article-title":"Oseltamivir-zanamivir bitherapy compared to oseltamivir monotherapy in the treatment of pandemic 2009 influenza A(H1N1) virus infections","volume":"96","author":"Escuret","year":"2012","journal-title":"Antivir. Res."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"4568","DOI":"10.1128\/AAC.00474-10","article-title":"Efficacy and Safety of Intravenous Peramivir for Treatment of Seasonal Influenza Virus Infection","volume":"54","author":"Kohno","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"5267","DOI":"10.1128\/AAC.00360-11","article-title":"Phase III Randomized, Double-Blind Study Comparing Single-Dose Intravenous Peramivir with Oral Oseltamivir in Patients with Seasonal Influenza Virus Infection","volume":"55","author":"Kohno","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"651","DOI":"10.3851\/IMP2442","article-title":"A clinical trial of intravenous peramivir compared with oral oseltamivir for the treatment of seasonal influenza in hospitalized adults","volume":"18","author":"Ison","year":"2012","journal-title":"Antivir. Ther."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1007\/s10156-012-0428-1","article-title":"Clinical effectiveness of neuraminidase inhibitors\u2014Oseltamivir, zanamivir, laninamivir, and peramivir\u2014For treatment of influenza A(H3N2) and A(H1N1)pdm09 infection: An observational study in the 2010\u20132011 influenza season in Japan","volume":"18","author":"Shobugawa","year":"2012","journal-title":"J. Infect. Chemother."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"834181","DOI":"10.1155\/2012\/834181","article-title":"Clinical Effectiveness of Peramivir in Comparison with Other Neuraminidase Inhibitors in Pediatric Influenza Patients","volume":"2012","author":"Hikita","year":"2012","journal-title":"Int. J. Pediatrics"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1086\/656802","article-title":"Long-Acting Neuraminidase Inhibitor Laninamivir Octanoate versus Oseltamivir for Treatment of Influenza: A Double-Blind, Randomized, Noninferiority Clinical Trial","volume":"51","author":"Watanabe","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Mawatari, M., Saito, R., Hibino, A., Kondo, H., Yagami, R., Odagiri, T., Tanabe, I., and Shobugawa, Y. (2019). Effectiveness of four types of neuraminidase inhibitors approved in Japan for the treatment of influenza. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0224683"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/irv.12147","article-title":"Comparison of the clinical effectiveness of zanamivir and laninamivir octanoate for children with influenza A (H3N2) and B in the 2011\u20132012 season","volume":"8","author":"Koseki","year":"2014","journal-title":"Influenza Other Resp. Viruses"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1093\/cid\/ciw255","article-title":"Long-acting Neuraminidase Inhibitor Laninamivir Octanoate as Post-exposure Prophylaxis for Influenza","volume":"63","author":"Kashiwagi","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_132","unstructured":"EMA, and Xofluza (2021, October 13). Highlights of Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/210854s001lbl.pdf."},{"key":"ref_133","unstructured":"EMA, and Xofluza (2021, October 13). Authorisation Details. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/xofluza#assessment-history-section."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJMoa1716197","article-title":"Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents","volume":"379","author":"Hayden","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.bsheal.2020.04.004","article-title":"Advanced researches on the inhibition of influenza virus by Favipiravir and Baloxavir","volume":"2","author":"Fang","year":"2020","journal-title":"Biosaf. Health."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"9633","DOI":"10.1038\/s41598-018-27890-4","article-title":"Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil","volume":"8","author":"Omoto","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"P3112","DOI":"10.1016\/j.xphs.2019.04.010","article-title":"Population Pharmacokinetics of Baloxavir Marboxil in Japanese Pediatric Influenza Patients","volume":"108","author":"Koshimichi","year":"2019","journal-title":"J. Pharm. Sci."},{"key":"ref_138","first-page":"422","article-title":"Pharmacokinetics and safety of a novel influenza treatment (baloxavir marboxil) in Korean subjects compared with Japanese subjects","volume":"15","author":"Kim","year":"2021","journal-title":"Am. Soc. Clin. Pharmacol. Theraputics."},{"key":"ref_139","unstructured":"EMA, and Xofluza (2021, October 13). Summary of Product Characteristics. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/xofluza-epar-product-information_en.pdf."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1097\/INF.0000000000002747","article-title":"Baloxavir Marboxil Single-dose Treatment in Influenza-infected Children","volume":"39","author":"Baker","year":"2020","journal-title":"Pediatric Infect. Dis. J."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.antiviral.2019.01.012","article-title":"Baloxavir marboxil in Japanese patients with seasonal influenza: Dose response and virus type\/subtype outcomes from a randomized phase 2 study","volume":"163","author":"Watanabe","year":"2019","journal-title":"Antivir. Res."},{"key":"ref_142","unstructured":"ClinicalTrials.gov (2021, October 13). A Study of S-033188 (Baloxavir Marboxil) Compared with Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza (CAPSTONE 1), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02954354."},{"key":"ref_143","unstructured":"ClinicalTrials.gov (2021, October 13). Study of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Patients with Influenza at High Risk of Influenza Complications (CAPSTONE 2), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT02949011."},{"key":"ref_144","unstructured":"ClinicalTrials.gov (2021, October 13). Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Healthy Pediatric Participants with Influenza-like Symptoms, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03629184?term=baloxavir+Marboxil&cond=Influenza&draw=2&rank=3."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S1473-3099(20)30004-9","article-title":"Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): A randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Ison","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"ref_146","unstructured":"ClinicalTrials.gov (2021, October 13). Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Healthy Pediatric Participants from Birth to <1 Year with Influenza-like Symptoms, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03653364?term=baloxavir+Marboxil&cond=Influenza&draw=2&rank=1."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1056\/NEJMoa1915341","article-title":"Baloxavir marboxil for prophylaxis against influenza in household contacts","volume":"383","author":"Ikematsu","year":"2020","journal-title":"N. Engl. J. Medicine."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40780-020-00178-4","article-title":"Efficacy of baloxavir marboxil on household transmission of influenza infection","volume":"6","author":"Umemura","year":"2020","journal-title":"J. Pharm. Health Care Sci."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"4110","DOI":"10.1021\/acs.molpharmaceut.8b00531","article-title":"A small-molecule compound has anti-influenza A virus activity by acting as a \u2018\u2018PB2 inhibitor\u201d","volume":"15","author":"Liu","year":"2018","journal-title":"Mol. Pharm."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"e01432-20","DOI":"10.1128\/JVI.01432-20","article-title":"Discovery of a Novel Specific Inhibitor Targeting Influenza A Virus Nucleoprotein with Pleiotropic Inhibitory Effects on Various Steps of the Viral Life Cycle","volume":"95","author":"Yang","year":"2021","journal-title":"J. Virol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"43","DOI":"10.12938\/bmfh.2020-019","article-title":"Anti-Influenza virus effects of Enterococcus faecalis KH2 and Lactobacillus plantarum SNK12 RNA","volume":"40","author":"Watanabe","year":"2021","journal-title":"Biosci. Microbiota Food Health"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"479718","DOI":"10.1155\/2013\/479718","article-title":"The Effectiveness and Mechanism of Toona sinensis Extract Inhibit Attachment of Pandemic Influenza A (H1N1) Virus","volume":"2013","author":"You","year":"2013","journal-title":"Evid. Based Complement Alternat. Med."},{"key":"ref_153","first-page":"458","article-title":"Anti-pandemic influenza A (H1N1) virus potential of catechin and gallic acid. Journal of the Chinese Medical Association","volume":"81","author":"You","year":"2018","journal-title":"JCMA"}],"container-title":["International Journal of Environmental Research and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1660-4601\/19\/5\/3018\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:32:08Z","timestamp":1760135528000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1660-4601\/19\/5\/3018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,4]]},"references-count":153,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,3]]}},"alternative-id":["ijerph19053018"],"URL":"https:\/\/doi.org\/10.3390\/ijerph19053018","relation":{},"ISSN":["1660-4601"],"issn-type":[{"value":"1660-4601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,4]]}}}